This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MCT-125

MultiCell Technologies, Inc.

Drug Names(s): LAX-202

Description: LAX-202 is a combination of an atypical antidepressant and an amino acid. LAX-202 is designed to reduce the levels of fatigue in MS patients.

Deal Structure: In January 2006, MultiCell exclusively licensed MCT-125 from Amarin. Under the terms of the agreement, Amarin could receive up to $275 million in milestone payments and cumulative royalty payments during the same period.

Partners: Amarin Corporation plc


MCT-125 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug